Posters
PRK, LASIK and femtoLASIK: visual outcomes one year
Poster Details
First Author: J. Reyes-Torres SPAIN
Co Author(s): F. Duch Mestres I. Blanco Dominguez M. Marti
Abstract Details
Purpose:
To compare the results of photorefractive keratectomy (PRK), laser assisted in situ keratomileusis (LASIK) and femtosecond laser assisted LASIK (femtoLASIK), over a 1-year follow-up.
Setting:
Refractive Surgery Department, Institut CatalĂ de Retina. Barcelona, Spain.
Methods:
This comparative retrospective study includes the refractive outcomes of 318 eyes, corresponding to: PRK (90), LASIK (150) and femtoLASIK (78) respectively, from the clinical records from myopic patients who underwent laser refractive surgery at the Department of Refractive Surgery of the Institut CatalĂ de Retina (Barcelona, Spain) between January and December 2013. To be included, the patient had to have completed 1-year follow-up. Uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), change in spherical equivalent (SE), percentage of eyes within +/- 0.5D from the emmetropia target among the three surgical techniques were studied.
Results:
A total of 318 eyes of 91 women and 68 men with an average age of 31.5 years were included in this study. Preoperative UDVA were equal to or less tan 0.15 in 85.5% of patientes. During the first postoperative month, UDVA was equal or better tan 0.8 in 91.1% of patients who underwent PRK, 98% of patients operated by LASIK and 97,4% of femtoLASIK respectively. At 1-year follow-up, the spherical equivalent (SE) was -0.05, -0.13, -0.10 diopters for PRK, LASIK and femtoLASIK respectively. At 1-year follow-up, CDVA was 1.0 in all cases.
Conclusions:
In this study, the average UDVA at 1-month follow-up is better in lamellar techniques (LASIK, femtoLASIK) compared to the surface ablation (PRK). This difference does not appear to be sustained in time, since the SE at 1-year follow-up is equal or better in the PRK compared to the lamellar technique. This study is currently in phase of statistical analysis prior to publication.
Financial Disclosure:
NONE